AIM ImmunoTech Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. Amounts below are in U.S. dollars; financial statement figures are generally in millions unless stated otherwise.
Business context
AIM is a clinical-stage immunopharmaceutical company focused primarily on Ampligen (rintatolimod), which it is developing for cancers, ME/CFS and post-COVID conditions, as well as antiviral uses. Ampligen is not FDA-approved or marketed in the United States; it is approved in Argentina for severe CFS, but commercial distribution there was still awaiting final regulatory and product-release steps. Alferon N Injection is FDA-approved for genital warts, but production of new inventory is on hold.
Financial results and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | $49,000 | $33,000 |
| Research and development | $2.052 million | $1.036 million |
| General and administrative | $2.292 million | $2.072 million |
| Operating loss | $4.295 million | $3.152 million |
| Net loss | $3.661 million | $3.820 million |
| Basic and diluted loss per share | $0.08 | $0.08 |
| Net cash used in operating activities | $3.680 million | $2.758 million |
Revenue came from the Ampligen cost-recovery program. With revenue of only $49,000 and no production costs reported for the quarter, a meaningful operating margin comparison is not informative. The company reported a $203,000 investment gain and a $255,000 gain from sale of income tax operating losses, which partly offset operating costs.
At March 31, 2023, cash and cash equivalents were $23.395 million and marketable securities were $7.454 million, for combined cash and securities of $30.849 million. Combined liquidity declined about $3.341 million from year-end 2022. Total assets were $37.462 million; total liabilities were about $2.652 million, including $815,000 of operating lease liabilities. The filing reports no conventional borrowings. Cash used in investing activities was $78,000, while financing activities provided $100,000 from a stock issuance.
Changes versus the prior comparable period
- Revenue increased $16,000, or approximately 48%, but remained immaterial relative to operating expenses.
- R&D expense increased about $1.017 million, primarily reflecting higher spending on clinical programs, contractors and rent. G&A expense rose $220,000.
- Net loss narrowed by approximately $158,000, mainly because the investment result improved from a $934,000 loss to a $203,000 gain. This improvement more than offset the higher operating loss.
- Operating cash use increased by $922,000 year over year. Common shares outstanding increased from 48.084 million at December 31, 2022 to 48.407 million at March 31, 2023.
Outlook, risks and notable items
- Management stated that current financial resources were expected to fund anticipated operating needs and current clinical trials for approximately 24 months. AIM expects no material operating revenue in the near future and may need additional financing; future equity financing could dilute shareholders.
- The company’s Phase 2 AMP-270 pancreatic cancer trial was recruiting. Management estimated the study would cost approximately $8.2 million and take about 4.6 years. The Phase 2 AMP-518 post-COVID study was proceeding under an amended protocol; its estimated cost was approximately $4.4 million.
- Major risks include clinical-trial outcomes, FDA and foreign regulatory requirements, manufacturing and supply capacity, commercialization prospects, and the need for additional capital. Ampligen’s U.S. NDA for ME/CFS received an FDA Complete Response Letter in 2013, and further studies and analyses remain necessary.
- In April 2023, AIM entered an equity distribution agreement allowing up to $8.5 million of common stock sales, with a 3% agent fee. The filing reports only 969 shares sold under the agreement after quarter-end, for approximately $485 gross proceeds.
- Subsequent events included a May 2023 amendment to the company’s shareholder rights plan, with a 15% ownership trigger and expiration scheduled for May 12, 2028. AIM also reported ongoing BioLife litigation; the court’s rulings left uncertainty over the company’s damages theories and potential appeal.
Key facts for investors to verify
- Whether AMP-270 and AMP-518 enrollment, timelines and spending remain consistent with management’s estimates, and what clinical milestones or results have since been reported.
- Whether the stated approximately 24-month liquidity runway remains supportable given quarterly operating cash use, trial commitments and potential financing needs.
- Whether Argentina’s remaining inspection and product-release requirements have been completed and commercial sales have begun; also verify the path and timing for resuming Alferon production.
- Clarify the filing’s differing AMP-511 enrollment disclosures: one passage reports 12 enrolled patients, while another reports 10, including four post-COVID patients.
- Review the full rights-plan terms and subsequent disclosures, as well as developments in the BioLife litigation and any further equity sales or dilution.